Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenovirus
Researchers from Harvard University publish new studies and findings in the area of adenovirus
January 28th, 2009
"A recombinant adenovirus serotype 5 ( rAd5) vector- based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans(1,2). Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys ( Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 ( ref. 3)," scientists in the United States report. "Here we show that an improved T- cell- based vaccine regimen using two serologically distinct adenovirus vectors afforded substantially improved protective efficacy in this challenge...
Source: Vaccine Weekly (2009-01-28)
|
